Upsher-Smith Laboratories has launched three new products – Fluvoxamine Maleate Tablets, Clonidine Hydrochloride Extended-Release Tablets, and Haloperidol Tablets, USP, to expand its generic portfolio.

According to the US pharma company, the market for the three generic drugs had combined sales of around $102.5 million in the US for the 12 months ending December 2019, as per IQVIA.

Upsher-Smith Laboratories said that it has committed to aggressively expand the number of generic drugs in its portfolio. In the next few years, the US pharma company aims to significantly grow its pipeline by striking internal research and development and external partnerships.

Upsher-Smith Laboratories said that its effort is being backed by an investment in infrastructure with the construction of a drug manufacturing facility at its headquarters in Minnesota.

Rusty Field – President and CEO of Upsher-Smith Laboratories said: “We enter this new decade not only with our most aggressive growth plan in history, but also prepared to meet the challenging market conditions that lie ahead.

“We’re proud of our strong reputation as a trusted partner in the generic marketplace and look forward to delivering even more affordable options to patients and healthcare professionals.”

  Clonidine Hydrochloride Extended-Release Tablets, Fluvoxamine Maleate Tablets, Haloperidol Tablets, IQVIA, Minnesota, Rusty Field, Upsher-Smith Laboratories